|
Characteristic
|
Heart transplant patients
|
|---|
|
n= 60
|
|---|
|
Male sex
|
34 (56.7%)
|
|
Age (years)
|
42.1± 11.5
|
|
Weight (kg)
|
61.3 ± 13.4
|
|
Height (cm)
|
162.5 ± 10.3
|
|
Body surface area (m2)
|
1.7 ± 0.2
|
|
Primary disease
|
|
Chagasic cardiomyopathy
|
22 (36.7%)
|
|
Idiopathic dilated cardiomyopathy
|
21 (35.0%)
|
|
Ischemic cardiomyopathy
|
7 (11.7%)
|
|
Valvular cardiomyopathy
|
5 (8.3%)
|
|
Hypertensive cardiomyopathy
|
4 (6.7%)
|
|
CTRCD
|
1 (1.6%)
|
|
Hypertension
|
12 (20.0%)
|
|
Diabetes
|
12 (20.0%)
|
|
Smoking
|
17 (28.3%)
|
|
Time since transplantation (months)
|
6
|
|
Medication
|
|
Corticosteroid
|
63 (95.5%)
|
|
Mycophenolate mofetil
|
62 (93.9%)
|
|
Tacrolimus
|
45 (68.2%)
|
|
Cyclosporine
|
21 (31.8%)
|
|
Sirolimus
|
4 (6.1%)
|
|
Azathioprine
|
4 (6.1%)
|
|
Statin
|
61 (92.4%)
|
|
CCB
|
56 (84.5%)
|
|
Betablocker
|
11 (16.7%)
|
|
ACEI/ARB
|
11 (16.7%)
|
- The values are presented as the mean (standard deviation) or number (percentage)
- CTRCD Cancer therapeutic-related cardiac dysfunction; ACEI angiotensin converting enzyme inhibitor; ARB aldosterone receptor blocker; CCB calcium channel blocker
